AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
vosoritide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| natriuretic peptides | 5480 | 1480724-61-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Vosoritide is a modified type C natriuretic peptide (CNP). In patients with achondroplasia, endochondral bone growth is negatively regulated due to a gain of function mutation in fibroblast growth factor receptor 3 (FGFR3). Binding of vosoritide to natriuretic peptide receptor-B (NPR-B) antagonises FGFR3 downstream signalling by inhibiting the extracellular signal-regulated kinases 1 and 2 (ERK1/2) in the mitogen-activated protein kinase (MAPK) pathway at the level of rapidly accelerating fibrosarcoma serine/threonine protein kinase (RAF-1). As a result, vosoritide, like CNP, acts as a positive regulator of endochondral bone growth as it promotes chondrocyte proliferation and differentiation.
|
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 26, 2021 | EMA | BIOMARIN INTERNATIONAL LIMITED | |
| Nov. 19, 2021 | FDA | BIOMARIN PHARM | |
| June 20, 2022 | PMDA | BIOMARIN PHARMACEUTICAL K.K |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Foramen magnum stenosis | 115.51 | 54.94 | 11 | 48 | 178 | 90628210 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Foramen magnum stenosis | 152.32 | 55.52 | 12 | 94 | 3 | 110589190 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | M05BX07 | MUSCULO-SKELETAL SYSTEM DRUGS FOR TREATMENT OF BONE DISEASES DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION Other drugs affecting bone structure and mineralization |
| FDA CS | M0029831 | Natriuretic Peptide, C-Type |
| FDA EPC | N0000193980 | C-type Natriuretic Peptide Analog |
Related Drugs by ATC class:
M05BX Other drugs affecting bone structure and mineralization 8 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Achondroplasia | indication | 86268005 | DOID:4480 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.4MG/VIAL | VOXZOGO | BIOMARIN PHARM | N214938 | Nov. 19, 2021 | RX | POWDER | SUBCUTANEOUS | RE48267 | May 20, 2030 | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES |
| 0.56MG/VIAL | VOXZOGO | BIOMARIN PHARM | N214938 | Nov. 19, 2021 | RX | POWDER | SUBCUTANEOUS | RE48267 | May 20, 2030 | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES |
| 1.2MG/VIAL | VOXZOGO | BIOMARIN PHARM | N214938 | Nov. 19, 2021 | RX | POWDER | SUBCUTANEOUS | RE48267 | May 20, 2030 | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES |
| 0.4MG/VIAL | VOXZOGO | BIOMARIN PHARM | N214938 | Nov. 19, 2021 | RX | POWDER | SUBCUTANEOUS | 8198242 | June 11, 2035 | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES |
| 0.56MG/VIAL | VOXZOGO | BIOMARIN PHARM | N214938 | Nov. 19, 2021 | RX | POWDER | SUBCUTANEOUS | 8198242 | June 11, 2035 | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES |
| 1.2MG/VIAL | VOXZOGO | BIOMARIN PHARM | N214938 | Nov. 19, 2021 | RX | POWDER | SUBCUTANEOUS | 8198242 | June 11, 2035 | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES |
| 0.4MG/VIAL | VOXZOGO | BIOMARIN PHARM | N214938 | Nov. 19, 2021 | RX | POWDER | SUBCUTANEOUS | 10646550 | Aug. 1, 2036 | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES |
| 0.4MG/VIAL | VOXZOGO | BIOMARIN PHARM | N214938 | Nov. 19, 2021 | RX | POWDER | SUBCUTANEOUS | 11590204 | Aug. 1, 2036 | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES |
| 0.4MG/VIAL | VOXZOGO | BIOMARIN PHARM | N214938 | Nov. 19, 2021 | RX | POWDER | SUBCUTANEOUS | 11911446 | Aug. 1, 2036 | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES |
| 0.4MG/VIAL | VOXZOGO | BIOMARIN PHARM | N214938 | Nov. 19, 2021 | RX | POWDER | SUBCUTANEOUS | 12514906 | Aug. 1, 2036 | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES |
| 0.56MG/VIAL | VOXZOGO | BIOMARIN PHARM | N214938 | Nov. 19, 2021 | RX | POWDER | SUBCUTANEOUS | 10646550 | Aug. 1, 2036 | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES |
| 0.56MG/VIAL | VOXZOGO | BIOMARIN PHARM | N214938 | Nov. 19, 2021 | RX | POWDER | SUBCUTANEOUS | 11590204 | Aug. 1, 2036 | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES |
| 0.56MG/VIAL | VOXZOGO | BIOMARIN PHARM | N214938 | Nov. 19, 2021 | RX | POWDER | SUBCUTANEOUS | 11911446 | Aug. 1, 2036 | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES |
| 0.56MG/VIAL | VOXZOGO | BIOMARIN PHARM | N214938 | Nov. 19, 2021 | RX | POWDER | SUBCUTANEOUS | 12514906 | Aug. 1, 2036 | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES |
| 1.2MG/VIAL | VOXZOGO | BIOMARIN PHARM | N214938 | Nov. 19, 2021 | RX | POWDER | SUBCUTANEOUS | 10646550 | Aug. 1, 2036 | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES |
| 1.2MG/VIAL | VOXZOGO | BIOMARIN PHARM | N214938 | Nov. 19, 2021 | RX | POWDER | SUBCUTANEOUS | 11590204 | Aug. 1, 2036 | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES |
| 1.2MG/VIAL | VOXZOGO | BIOMARIN PHARM | N214938 | Nov. 19, 2021 | RX | POWDER | SUBCUTANEOUS | 11911446 | Aug. 1, 2036 | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES |
| 1.2MG/VIAL | VOXZOGO | BIOMARIN PHARM | N214938 | Nov. 19, 2021 | RX | POWDER | SUBCUTANEOUS | 12514906 | Aug. 1, 2036 | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES |
| 0.4MG/VIAL | VOXZOGO | BIOMARIN PHARM | N214938 | Nov. 19, 2021 | RX | POWDER | SUBCUTANEOUS | 12233106 | July 11, 2042 | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES |
| 0.56MG/VIAL | VOXZOGO | BIOMARIN PHARM | N214938 | Nov. 19, 2021 | RX | POWDER | SUBCUTANEOUS | 12233106 | July 11, 2042 | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES |
| 1.2MG/VIAL | VOXZOGO | BIOMARIN PHARM | N214938 | Nov. 19, 2021 | RX | POWDER | SUBCUTANEOUS | 12233106 | July 11, 2042 | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 0.4MG/VIAL | VOXZOGO | BIOMARIN PHARM | N214938 | Nov. 19, 2021 | RX | POWDER | SUBCUTANEOUS | Oct. 20, 2026 | NEW PATIENT POPULATION |
| 0.56MG/VIAL | VOXZOGO | BIOMARIN PHARM | N214938 | Nov. 19, 2021 | RX | POWDER | SUBCUTANEOUS | Oct. 20, 2026 | NEW PATIENT POPULATION |
| 1.2MG/VIAL | VOXZOGO | BIOMARIN PHARM | N214938 | Nov. 19, 2021 | RX | POWDER | SUBCUTANEOUS | Oct. 20, 2026 | NEW PATIENT POPULATION |
| 0.4MG/VIAL | VOXZOGO | BIOMARIN PHARM | N214938 | Nov. 19, 2021 | RX | POWDER | SUBCUTANEOUS | Nov. 19, 2026 | NEW CHEMICAL ENTITY |
| 0.56MG/VIAL | VOXZOGO | BIOMARIN PHARM | N214938 | Nov. 19, 2021 | RX | POWDER | SUBCUTANEOUS | Nov. 19, 2026 | NEW CHEMICAL ENTITY |
| 1.2MG/VIAL | VOXZOGO | BIOMARIN PHARM | N214938 | Nov. 19, 2021 | RX | POWDER | SUBCUTANEOUS | Nov. 19, 2026 | NEW CHEMICAL ENTITY |
| 0.4MG/VIAL | VOXZOGO | BIOMARIN PHARM | N214938 | Nov. 19, 2021 | RX | POWDER | SUBCUTANEOUS | Nov. 19, 2028 | TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WHO ARE 5 YEARS OF AGE AND OLDER WITH OPEN EPIPHYSES |
| 0.56MG/VIAL | VOXZOGO | BIOMARIN PHARM | N214938 | Nov. 19, 2021 | RX | POWDER | SUBCUTANEOUS | Nov. 19, 2028 | TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WHO ARE 5 YEARS OF AGE AND OLDER WITH OPEN EPIPHYSES |
| 1.2MG/VIAL | VOXZOGO | BIOMARIN PHARM | N214938 | Nov. 19, 2021 | RX | POWDER | SUBCUTANEOUS | Nov. 19, 2028 | TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WHO ARE 5 YEARS OF AGE AND OLDER WITH OPEN EPIPHYSES |
| 0.4MG/VIAL | VOXZOGO | BIOMARIN PHARM | N214938 | Nov. 19, 2021 | RX | POWDER | SUBCUTANEOUS | Oct. 20, 2030 | TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS LESS THAN 5 YEARS OF AGE WITH ACHONDROPLASIA WITH OPEN EPIPHYSES |
| 0.56MG/VIAL | VOXZOGO | BIOMARIN PHARM | N214938 | Nov. 19, 2021 | RX | POWDER | SUBCUTANEOUS | Oct. 20, 2030 | TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS LESS THAN 5 YEARS OF AGE WITH ACHONDROPLASIA WITH OPEN EPIPHYSES |
| 1.2MG/VIAL | VOXZOGO | BIOMARIN PHARM | N214938 | Nov. 19, 2021 | RX | POWDER | SUBCUTANEOUS | Oct. 20, 2030 | TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS LESS THAN 5 YEARS OF AGE WITH ACHONDROPLASIA WITH OPEN EPIPHYSES |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Atrial natriuretic peptide receptor 2 | Enzyme | ACTIVATOR | EC50 | 8.77 | DRUG LABEL | DRUG LABEL |
External reference:
| ID | Source |
|---|---|
| 7SE5582Q2P | UNII |
| C4519745 | UMLSCUI |
| CHEBI:755767 | CHEBI |
| CHEMBL3707276 | ChEMBL_ID |
| 119058036 | PUBCHEM_CID |
| DB11928 | DRUGBANK_ID |
| 10022 | INN_ID |
| C000632572 | MESH_SUPPLEMENTAL_RECORD_UI |
| 9068 | IUPHAR_LIGAND_ID |
| D11190 | KEGG_DRUG |
| 1660971000168105 | SNOMEDCT_US |
| 1661051000168106 | SNOMEDCT_US |
| 4040998 | VANDF |
| 353929 | MMSL |
| 40117 | MMSL |
| d09828 | MMSL |
| 018891 | NDDF |
| 2586354 | RXNORM |
| 7SE5582Q2P | INXIGHT DRUGS |
Pharmaceutical products:
None